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Herein, we demonstrate that HCMV miR-UL112-5p
targets ERAP1, thereby inhibiting the processing
and presentation of the HCMV pp65495-503 peptide
to specific CTLs. In addition, we show that the
rs17481334 G variant, naturally occurring in the
ERAP1 30 UTR, preserves ERAP1 from miR-UL112-
5p-mediated degradation. Specifically, HCMV miR-
UL112-5p binds the 30 UTR of ERAP1 A variant, but
not the 30 UTR of ERAP1 G variant, and, accordingly,
ERAP1 expression is reduced both at RNA and pro-
tein levels only in human fibroblasts homozygous
for the A variant. Consistently, HCMV-infected GG
fibroblasts were more efficient in trimming viral
antigens and being lysed by HCMV-peptide-specific
CTLs. Notably, a significantly decreased HCMV
seropositivity was detected among GG individuals
suffering from multiple sclerosis, a disease model
in which HCMV is negatively associated with adult-
onset disorder. Overall, our results identify a resis-
tance mechanism to HCMV miR-UL112-5p-based846 Cell Reports 20, 846–853, July 25, 2017 ª 2017 The Author(s).
This is an open access article under the CC BY license (http://creativeimmune evasion strategy with potential implications
for individual susceptibility to infection and other
diseases.INTRODUCTION
Human cytomegalovirus (HCMV) is a b-herpesvirus that causes
widespread, persistent infection, and it is often lethal in subjects
with impaired immunity (Stern-Ginossar et al., 2012). HCMV has
evolved multiple strategies to interfere with innate and adaptive
immune responses. Virtually, every single step within the MHC
class I antigen processing and presentation pathway is targeted
by viral proteins (van de Weijer et al., 2015), thus indicating that
recognition of viral peptides by CD8+ T cells is a key event in the
elimination of HCMV-infected cells.
In addition to viral proteins, HCMV also deploys virally en-
coded microRNAs (miRNAs) to manipulate host immune re-
sponses. Currently, 24 mature miRNAs encoded by HCMV
have been identified to target both viral and host genes involved
in immune defense, chromatin remodeling, cell cycle regulation,
apoptosis, signal transduction, and vesicular trafficking (Grey
et al., 2007, 2010; Hook et al., 2014a, 2014b; Kim et al., 2015;
Lee et al., 2012; Tirabassi et al., 2011). In particular, three viralcommons.org/licenses/by/4.0/).
miRNAs have been found to affect components of the immune
system: miR-UL112-1 targets MICB, a stress-induced ligand
of the natural killer (NK) cell activating receptor NKG2D, which
is crucial for NK cell-mediated killing of viral-infected cells
(Stern-Ginossar et al., 2007); miR-UL148D targets the chemo-
kine CCL5, which limits viral infection by recruiting immune cells
to the site of infection (Kim et al., 2012); and miR-US4-1 targets
ERAP1, a key component of the antigen processing that trims
precursors into peptides of the correct length to bind MHC
class I molecules, resulting in an impaired production of many
viral epitopes and a reduced anti-viral CD8+ T cell response
(Kim et al., 2011).
Studies in ERAP1-deficient mice have demonstrated that
ERAP1 is required for presentation of several viral epitopes,
and its absence affects anti-viral CD8+ T cell responses (Blan-
chard et al., 2010; Firat et al., 2007; Saveanu et al., 2005; Yan
et al., 2006). In humans, DNA sequence variation in ERAP1
has been associated to genetic-risk effects in a number of
immune-mediated diseases, including ankylosing spondylitis,
psoriasis, Behc¸et’s disease, and multiple sclerosis (MS) (Strati-
kos et al., 2014). Functional studies have established that these
variants affect ERAP1 activity, resulting in changes in the reper-
toire of antigenic peptides (Reeves et al., 2014), which is critical
for shaping innate and adaptive immune responses (Cifaldi
et al., 2011, 2015; James et al., 2013). The importance of
ERAP1 trimming for immune recognition of virus-infected cells
is demonstrated by several findings, including the evolution
of escape mutations impairing ERAP1 activity and resulting in
decreased CD8+ T cell response (Draenert et al., 2004; Tenzer
et al., 2009).
Functional genetic variations in miRNA processing machinery,
genes, and target sites, named miR-single-nucleotide polymor-
phisms (miR-SNPs), have attracted special attention due to their
involvement in several types of cancer (Ryan et al., 2010). These
variants can affect the transcription of target genes, pre-miRNA
processing, and/or modulate miRNA-mRNA interactions by
affecting miRNA binding to target sites. It is therefore possible
to envisage a complex scenario where ERAP1 functional poly-
morphisms may be relevant to individual susceptibility to both
HCMV infection and (directly or indirectly) autoimmunity, through
gene-environment (exposure) interactions.
In this study, we demonstrate that HCMV miR-UL112-5p spe-
cifically targets ERAP1, thereby inhibiting the processing and
presentation of the HCMV pp65495-503 peptide to specific cyto-
toxic CD8+ T cells. In addition, we found a naturally occurring
variant in the 30 UTR of the ERAP1 gene (SNP rs17481334),





Recent deep-sequencing analyses of small RNAs from HCMV-
infected human fibroblast cells led to the identification of novel
viral miRNA precursors and refinement of miRNA annotations
(Meshesha et al., 2012; Stark et al., 2012). In particular, se-
quences obtained for miR-US4-1 (now miR-US4-5p) resultedin being shifted by 5 bp at the 50 end (Figure S1A), thereby
complicating the interpretation of the seed-mediated ERAP1 30
UTR targeting described so far (Kim et al., 2011). Regardless of
the correct sequence of miR-US4-1, ERAP1 protein decreased
during infection with wild-type HCMV, whereas it remained un-
changed in cells infected with a mutant HCMV strain carrying a
defective processing of the miR-US4-1 primary transcript, sug-
gesting a key role for that region of ERAP1 30 UTR in viral-medi-
ated immune evasion.
An A-to-G polymorphism mapping to the 30 UTR of the ERAP1
mRNA (SNP rs17481334), and corresponding to one of the
mutated nucleotides involved in the study by Kim et al. (Fig-
ure S1A), was predicted to disrupt the consensus sequence for
miR-US4-1 binding. Because rs17481334 did not match the
sequence of mature miR-US4-5p, we looked for other HMCV
miRNAs targeting the region encompassing this genetic variant.
The RNAhybrid algorithm (Rehmsmeier et al., 2004) predicted
the miR-UL112-5p to directly target ERAP1 30 UTR in that posi-
tion (Figure S1B). This interaction was validated in vitro using
ERAP1 30 UTR dual-luciferase assays in 293T cells ectopically
expressing miR-UL112-5p or a mutated version of miR-UL112-
5pwith a single base substitution corresponding to the SNP (Fig-
ure S1B). A significant decrease in luciferase activity was
observed for the cells expressing the rs17481334 A variant of
ERAP1 30 UTR and the wild-type miR-UL112-5p, as well as for
those expressing the rs17481334 G variant and the mutated
miR-UL112-5p (Figure 1A). These data suggest that miR-
UL112-5p directly targeted ERAP1 in the consensus site and
that this interaction is affected by the SNP.
To test whether this differential binding couldmodulate ERAP1
expression, endogenous ERAP1 mRNA and protein levels were
measured in fibroblasts isolated from individuals homozygous
for ERAP1 rs17481334 A or G alleles equally transfected with
wild-type or mutated miR-UL112-5p (Figure S1C). In these ex-
periments, miR-UL112-5p induced 57% downregulation of
ERAP1 mRNA expression in fibroblasts from the rs17481334
AA individual, but had no effect in rs17481334 GG fibroblast
cells. Conversely, the mutated miR-UL112-5p had no effect in
AA cells, whereas it induced 40% downregulation of ERAP1
mRNA expression in rs17481334 GG cells (Figure 1B). Of note,
ERAP1 mRNA was reduced at similar levels in fibroblasts from
both individuals by a siRNA targeting a coding region of
ERAP1 (siERAP1) (88% and 91% in rs17481334 AA and GG fi-
broblasts, respectively) (Figure 1B). Virtually identical results
were obtained in immunoblot experiments under the same con-
ditions (Figure 1C).
HCMV Infection Fails to Downregulate ERAP1
Expression in rs17481334 GG Fibroblasts
Fibroblasts from rs17481334 AA and GG homozygous individ-
uals were infected with the HCMV laboratory strain AD169 at
two different multiplicity of infections (MOI). At 3 days post-infec-
tion (dpi), fibroblasts were infected at a similar level, as eval-
uated by expression of viral immediate-early antigens (IE1 and
IE2) and MHC class I downregulation (Figure 2A). HCMV-in-
fected cells sorted for reduced MHC class I expression (Fig-
ure 2B; Figure S2) showed a reduced overall amount of ERAP1
protein reaching a maximal decrease of 60% in fibroblastsCell Reports 20, 846–853, July 25, 2017 847
Figure 1. rs17481334 Variant G Abolishes HCMV miR-UL112-5p
Binding to the 30 UTR of ERAP1
(A) Luciferase assays of 293T cells transfected with dual-luciferase reporter
vector bearing the rs17481334 A or G variant of ERAP1 30 UTR and either a
control scrambled sequence (miR-scr), miR-UL112-5p, or mutated miR-
UL112-5p (Mut miR-UL112-5p). Data are representative of five independent
experiments.
(B and C) Real-time qPCR (B) and representative immunoblotting analysis (C)
of ERAP1 expression in fibroblasts with AA or GG genotypes, transfected with
miR-scr, miR-UL112-5p, Mut miR-UL112-5p, or siERAP1. In (C), an ERp57
antibody (Ab) is used for normalization. Densitometric analysis of ERp57-
normalized ERAP1 values of three independent experiments is shown below.
Mean ± SD; *p < 0.05, **p < 0.001, ***p < 0.0001.from AA individuals at MOI 5, as compared to uninfected cells
(Figure 2C). Conversely, no changes of ERAP1 protein expres-
sion were detected in HCMV-infected fibroblasts from the GG in-
dividual (Figure 2C), suggesting that the presence of G at the848 Cell Reports 20, 846–853, July 25, 2017rs17481334 30 UTR site prevents ERAP1 downregulation during
HCMV infection. Interestingly, the overall amount of ERAP1 pro-
tein remained unchanged at different time points in cells infected
with a modified HCMV AD169 strain (HCMVDUL112) deleted in
the UL114 gene encompassing themiR-UL112-5p (Stern-Ginos-
sar et al., 2007) (Figure 2D).
rs17481334 Affects the ERAP1-Dependent HCMV
pp65495-503 CD8
+ T Cell Epitope Presentation during
HCMV Infection
To directly demonstrate the functional relevance of rs17481334
during HCMV infection, we tested the capability of fibroblasts
from AA and GG homozygous individuals to present the HLA-
A*0201-restricted immunodominant HCMV pp65495-503 epitope,
which is one of the well-known viral epitopes requiring ERAP1
activity for its in vitro generation (Urban et al., 2012). Thus,
we isolated fibroblasts from AA and GG homozygous HLA-
A*0201+ individuals expressing similar levels of ERAP1 and cell
surface HLA-A2 molecules, with a similar ability to process and
present HCMV pp65495-503 peptide to specific cytotoxic T lym-
phocytes (CTLs) (Figures S3A–S3G). Fibroblasts with these fea-
tures were infected with wild-type HCMV or HCMVDUL112 at
MOI 1, and their susceptibility to HLA-A*0201-restricted/
pp65495-503-specific CTLs was evaluated at 3 dpi. Although fi-
broblasts from either genotype were similar in relation to IE1/2
expression and MHC class I downregulation (Figure 3A), cells
from the GG individual infected with wild-type HCMV and
expressing unchanged levels of ERAP1 (Figure S3H), were killed
more efficiently than those from the AA individual, at all effector/
target ratios tested (Figure 3B). This different susceptibility to
CTL-mediated killing appeared to depend on miR-UL112-5p
targeting of ERAP1, because it was not evident in fibroblast
cells from AA and GG individuals infected with HCMVDUL112
(Figure 3B; Figure S3H). Consistently, GG fibroblasts stably
knocked down for ERAP1 were killed less efficiently than control
cells when infected with wild-type HCMV (Figures 3C and 3D;
Figure S4).
rs17481334 GG Genotype Associates with
HCMV-Seronegative Profile in MS Patients
The potential impact of the rs17481334 polymorphism in host-
virus interactions was studied by looking at HCMV serology
data in relation to genotype, considering the GG homozygous
combination the most likely to show biological effects. The
G allele occurs at minor allele frequency (MAF) of 0.121 in
Caucasians, with GG carriers representing 3% of the general
population (ensembl.org). Inspection of genome-wide associa-
tion study (GWAS) data from a Finnish general population
previously studied in relation to HCMV seropositivity (Kuparinen
et al., 2012) did not disclose any significant difference for
rs17481334 GG homozygotes (data not shown). However, as
shown in Figure 4, the same analysis performed in individuals
suffering from MS, a condition where HCMV infection has
been proposed to play a protective role (Sundqvist et al.,
2014; Waubant et al., 2011), detected 5-fold decreased odds
of HCMV seropositivity among GG patients compared to all
other individuals (p = 0.021; odds ratio [OR] = 0.193 [95% con-
fidence interval (CI), 0.041–0.913]).
Figure 2. rs17481334 Controls ERAP1
Expression in HCMV-Infected Fibroblasts
(A) Representative flow-cytometric analysis of
MHC class I cell surface expression and intracel-
lular IE1/IE2 (IE1/2) viral protein expression in fi-
broblasts with AA or GG genotypes infected with
HCMV AD169 strain at the indicated MOI, 3 days
after infection. The percentage of cells in each
quadrant is indicated.
(B) Gating strategy used to sort AD169-infected
cells based on the viral-mediated MHC class I
downregulation. MHC class I expression in unin-
fected and infected cells is shown in light and dark
gray histograms, respectively.
(C) Representative immunoblotting analysis of
ERAP1 and MHC class I expression in uninfected
(U) or HCMV AD169-infected fibroblasts with AA
or GG genotypes. Densitometric analysis of
ERp57-normalized ERAP1 values relative to unin-
fected fibroblasts from three independent experi-
ments is shown.
(D) Representative immunoblotting analysis of
ERAP1 in fibroblasts with AA genotype, either
uninfected (U) or infected with wild-type HCMV
AD169 (WT) or HCMVDUL112 (DUL112) at MOI
of 5 at 24, 48, and 72 hr after infection. Densito-
metric analysis of ERp57-normalized ERAP1
values relative to uninfected fibroblasts from three
independent experiments is shown. Mean ± SD;
*p < 0.05, **p < 0.001.DISCUSSION
In this study, we demonstrated that HCMV miR-UL112-5p tar-
gets ERAP1 and that the rs17481334 G variant naturally occur-
ring in the 30 UTR of the ERAP1 gene preserves ERAP1 from
miR-UL112-5p-mediated degradation. Accordingly, ERAP1
expression was reduced by miR-UL112-5p overexpression
both at RNA and protein levels in human fibroblasts from AA in-
dividuals, but not in fibroblasts from GG individuals. ConsistentCwith these results, AA fibroblasts infected
with the wild-type HCMV, but not with
the mutant miR-UL112-5p knockout vi-
rus, showed a lower amount of ERAP1
protein. HCMV-infected GG fibroblasts
were more efficient in trimming viral
antigens to generate immunogenic epi-
topes and more susceptible to elimina-
tion by HCMV-peptide-specific CTLs.
Hence, these data demonstrate that the
rs17481334 GG genotype hampers the
HCMV miR-UL112-5p-based immunoe-
vasion strategy.
HCMV has evolved to establish lifelong
latent infections in immunocompetent in-
dividuals, with periodic and spontaneous
reactivation. This asymptomatic coexis-
tence is reflected by a prompt response
of HCMV-specific T cells that dominate
the memory compartment of exposed in-dividuals, accounting for approximately 10% of total CD8+
T cells (Sylwester et al., 2005). Conversely, HCMV infection in in-
dividuals with either an immature or compromised immune sys-
tem (e.g., pre- or post-natal infants and transplant recipients,
leukemia, or HIV-infected patients, respectively) can cause
different diseases, the severity of which depends on the degree
of immunosuppression (Halenius and Hengel, 2014).
For a virus to survive in an immunocompetent host, it is essen-
tial to avoid the presentation of viral epitopes to CD8+ T cellsell Reports 20, 846–853, July 25, 2017 849
Figure 3. rs17481334 Affects pp65495-503 Epitope Presentation
(A) Representative flow-cytometric analysis of cell surface MHC class I
expression and intracellular IE1/2 viral protein expression of fibroblasts with
850 Cell Reports 20, 846–853, July 25, 2017(Halenius et al., 2015). In this context, HCMV has evolved several
strategies to target key components in the MHC class I antigen-
processing pathway, including ERAP1 (Kim et al., 2011). We at-
tempted to explore this possibility with our pilot study of HCMV
seropositivity in relation to ERAP1 rs17481334 genotype. Unsur-
prisingly, no significant finding could be detected at the level of
the general (Finnish) population, although we observed a signif-
icant association when we investigated the relationship between
GGgenotype and HCMV serology usingMS to ‘‘model’’ these in-
teractions. Given the variant allele frequency and the size of the
cohort examined, the obtained results, although limited to small
number of individuals, were statistically significant. Although the
true (if any) impact of GG genotype on HCMV infection, and
eventually MS onset, can only be assessed via large-scale
longitudinal epidemiological studies taking into account individ-
ual viral exposure, it is noteworthy that we observed a 5-fold
decreased likelihood (OR = 0.193) of seropositivity among GG
individuals with MS (that is, in a disease context where HCMV
infection has been proposed to play a protective role) compared
to other patients. Hence, although lacking mechanistic relation
to causality, these results are intriguing because they suggest
that important information may be gained by assessing multiple
factors at once and open up novel lines of investigation, where
the interplay between HCMV exposure, genotype-driven im-
mune responses, and ultimately disease (autoimmunity/cancer)
can be explored toward tailored preventive approaches. Consis-
tently, Li et al. (2011) identified a novel link between HCMV infec-
tion and essential hypertension, in which miR-UL112 was inde-
pendently associated with an increased risk of hypertension.
Of note, ERAP1 is also known to play a role in the regulation of
blood pressure through its involvement in the renin-angiotensin
system (Hattori et al., 2000). Further studies are warranted to
confirm and extend these findings, also in relation to the presence
of multiple SNP-expression quantitative trait loci (eQTLs) at the
ERAP1 locus, including rs17481334 where the G variant appears
to associatewith lower ERAP1 expression (https://gtexportal.org/).
In addition to the pp65495–503 epitope, ERAP1 is known to trim
many other immunogenic HCMV epitopes (Kim et al., 2011).
Experiments in the ERAAP/ mouse model have demonstrated
that ERAP1 controls the magnitude of CD8+ T cell response
during murine cytomegalovirus (mCMV) infection (Blanchard
et al., 2010). Although neither all HCMV nor mCMV-derived epi-
topes require ERAP1 activity for their generation, recent mass
spectrometry analyses have demonstrated that ERAP1 has aAA or GG genotypes both uninfected (U) or infected at MOI 1 with wild-type
HCMV AD169 (WT) or HCMVDUL112 (DUL112), 3 days after infection. The
percentage of cells in each quadrant is indicated.
(B) 51Cr-release assay of HCMV-infected fibroblasts of (A) co-cultured with
HLA-A2-restricted/pp65495-503-specific CTLs at the indicated effector/target
(E:T) ratio.
(C) Representative flow-cytometric analysis of cell surface MHC class I and
intracellular IE1/2 viral protein expression of shERAP1- or shCTRL-transduced
GG fibroblasts infected with wild-type HCMV at MOI 1, 3 days after infection.
The percentage of cells in each quadrant is indicated.
(D) 51Cr-release assay of HCMV-infectedGG fibroblasts of (C) co-culturedwith
HLA-A2-restricted/pp65495-503-specific CTLs at the indicated effector/target
(E:T) ratio. All data are representative of three independent experiments.
Mean ± SD; *p < 0.05, **p < 0.001.
Figure 4. rs17481334 Genotype and HCMV Serology in MS Patients
Serological anti-HCMV Ab profiles are reported for MS patients stratified
according to rs17481334 genotype.significant influence on the overall peptidome (Lo´pez de Castro
et al., 2016; Nagarajan et al., 2016).
In conclusion, we demonstrate that a variant in the 30 UTR
of ERAP1, a key component of MHC class I antigen processing,
impairs miR-UL112-5p-mediated mechanism of HCMV immu-
noevasion, with potential implications for the control of the
viral infection itself and, eventually, indirect effects on the risk
of HCMV-associated diseases.
EXPERIMENTAL PROCEDURES
30 UTR Luciferase Assay
HEK293T cells were co-transfected with 1.6 mg of pEZX-MT01 vectors
and 80 nmol/L miR-UL112-5p, mutated miR-UL112-5p (Mut miR-UL112-5p),
or scrambled control (Ambion) using Lipofectamine 2000 (Invitrogen). After
48 hr, luciferase activity was measured with a LucPair Duo-Luciferase Assay
Kit (Genecopoeia). Firefly luciferase activity was normalized to Renilla lucif-
erase activity.
Transfection, Viral Infections, and Peptide Pulsing
Fibroblasts were transfected with 200 nM of either miR-scramble, miR-UL112-
5p, Mut miR-UL112-5p (Ambion), or a siRNA targeting a coding region of
ERAP1 (Sigma-Aldrich) (Table S1) with Lipofectamine 2000. As control, cells
were transfected with the same amount of an oligo-FITC (Invitrogen) in order
to assess the efficiency at 24 hr post-transfection by fluorescence-activated
cell sorting (FACS) analysis. Fibroblasts were infected with HCMV strains at
80%–90% confluence in serum-free medium. After 2–3 hr of virus adsorption
at 37C, fresh growth medium was replaced (day 0). At 3 dpi, cells were
harvested and analyzed. In some experiments, fibroblasts were infected
either with a lentivirus containing pp65-GFP and sorted for GFP expression,
or with a non-target shRNA control vector (SHC002), or the ERAP1 shRNA
(TRCN0000060542) (Sigma-Aldrich) and selected with 2 mg/mL puromycin
for 3 days. For peptide pulsing, cells were seeded in 96-well flat-bottom plates
in triplicate and pulsed with 5 mg/mL pp65495-503 peptide. After 2 hr, fresh
growth medium was replaced.
Proliferation Assay and Chromium-Release Assay
For proliferation assays, infected or peptide-pulsed cells were seeded in
96-well flat-bottom plates in triplicate and incubated with HLA-A2-restricted/
pp65495-503-specific CD8
+ T cells. After 72-hr incubation at 37C, cells were
pulsed with 3H-thymidine (1 mg Ci/well; specific activity, 6.7 Ci/mmol;
PerkinElmer) and harvested after 18 hr. 3H-thymidine incorporation was
measured by standard procedures with Microbeta Trilux 1450 instrument
(PerkinElmer). For cytotoxic activity, 51Cr-labeled infected or peptide-pulsed
target cells (5 3 103 per well) were mixed with HLA-A2-restricted/
pp65495-503-specific CD8
+ T cells in 96-well plates in triplicate at various ratios
and incubated at 37C. After 5 hr of incubation, supernatant was collected, and
the 51Cr release was measured by a TopCount NXT b detector (PerkinElmer).All experimental groups were analyzed in triplicate, and the specific lysis was
determined as follows: 100 3 (experimental release  spontaneous release)/
(total release  spontaneous release). Spontaneous release lower than about
5% of the total release was observed in all assays.
MS Patient Cohort
Samples from 949 MS patients with ages between 16 and 70 years from the
Epidemiological Investigation of Multiple Sclerosis (EIMS) were included in this
study. EIMS is a nationwide population-based case-control study of incident
cases of MS in Sweden (Hedstro¨m et al., 2011). All of the cases fulfilled the
McDonald criteria for MS (Polman et al., 2005) and were examined and diag-
nosed by a neurologist at one of 30 recruiting centers in Sweden. Anti-HCMV
serological status was determined in plasma using ELISA as described previ-
ously (Sundqvist et al., 2014). The HCMV antigen was prepared from embryonic
fibroblasts infected with strain AD169 until complete cytopathic effect. Human
plasmasampleswereanalyzed induplicates,atadilutionof1/200.Alkalinephos-
phatase-conjugated, purified F(ab0 )2 fragment goat anti-human IgG was used
as conjugate (Jackson ImmunoResearch). The plates were read at 405 and
650nm inaMultiskanFCreader (ThermoFisherScientific). Cutoffwascalculated
byadding0.2optical density (OD)units to themeanabsorbancevalueof160 runs
of negative control samples. Plasma samples with OD values at cutoff were run
in 2-fold dilutions (1/100–1/12,800) and then judged as positive or negative.
Ethics Statement
Ethical approval for generating and analyzing human fibroblasts from skin bi-
opsies was obtained from the Institutional Review Board of the Hospital
Bambino Gesu`. Written informed consent was obtained from adult patients,
or the guardians of patients who were children. The EIMS study has been
approved by the Regional Ethical Review Board in Stockholm, Sweden
(http://www.epn.se). Written informed consent from all study participants or
their parents was obtained. Investigations were carried out according to
guidelines from the Declaration of Helsinki.
Statistical Analysis
Data are presented as mean, and error bars indicate the SD. Digital images of
western blots were analyzed by ImageJ (https://imagej.nih.gov/ij/index.html),
and statistical significance was assessed by the two-way ANOVA test. c2
test was used to analyze the different distribution of rs17481334 genotype fre-
quency in HCMV-positive and -negative Swedish MS cases.
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